Table 3 Safety, tolerability, and adverse effects of melatonin and placebo
From: Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial
Parameter | Melatonin | Placebo | Fisher’s P value |
|---|---|---|---|
N | 39 | 39 | Â |
Nausea, patients reporting "Yes" (N, %) | Â | Â | Â |
 Pre | 2/39 (5.1%) | 3/38 (7.9%) | 0.675 |
 Post | 3/38 (7.9%) | 4/36 (11.1%) | 0.707 |
Dizziness, patients reporting "Yes" (N, %) | Â | Â | Â |
 Pre | 8/39 (20.5%) | 8/38 (21.1%) | 1.00 |
 Post | 8/38 (21.1%) | 10/35 (28.6%) | 0.588 |
Fatigue, patients reporting "Yes" (N, %) | Â | Â | Â |
 Pre | 20/39 (51.3%) | 15/38 (39.5%) | 0.363 |
 Post | 23/38 (60.5%) | 19/36 (52.8%) | 0.639 |
Drowsiness, patients reporting "Yes" (N, %) | Â | Â | Â |
 Pre | 22/39 (56.4%) | 18/37 (48.6%) | 0.646 |
 Post | 22/37 (59.5%) | 17/36 (47.2%) | 0.352 |
Early morning awakening or sleep disturbances, patients reporting "Yes" (N, %) | Â | Â | Â |
 Pre | 19/39 (48.7%) | 22/37 (59.5%) | 0.368 |
 Post | 22/37 (59.5%) | 23/36 (63.9%) | 0.811 |